Navigation Links
British Artificial Intelligence Firm Announces Exclusive License Agreement with Janssen for Clinical Stage Drug Candidates, Facilitated by Johnson & Johnson Innovation
Date:11/8/2016

LONDON, November 8, 2016 /PRNewswire/ --

BenevolentAI, a leading British artificial intelligence ("AI") company today announced significant progress in one of its key ambitions; to improve and innovate the drug development process using AI technology and provide the best medicines to the right patients.  BenevolentAI has signed an exclusive license for a series of novel clinical stage drug candidates with Janssen Pharmaceutica NV ("Janssen"), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement was facilitated by the Johnson & Johnson Innovation Centre in London.

BenevolentAI has acquired a license to a select number of novel clinical stage drug candidates and   their extensive related portfolio of   patents.  BenevolentAI scientists leveraged the AI technology to evaluate the potential of these small molecule compounds. The results indicate that there is strong promise to develop new medicines for hard to treat diseases.  

Under the terms of the license agreement, BenevolentAI will have the sole right to develop, manufacture and commercialise these novel drug candidates in all indications and in all territories. This agreement will enable BenevolentAI to accelerate its development pipeline and use its unique artificial intelligence technology to explore and provide a rich source of clinical data. BenevolentAI intends to begin late stage Phase IIb clinical trials in mid 2017. Financial terms were not disclosed.

Jackie Hunter, Board Director of BenevolentAI and CEO of BenevolentAI Bio, commented:

"We are delighted to have acquired rights to these compounds under a license agreement from Janssen. The agreement adds further depth to our clinical and pre-clinical development pipeline and marks a very exciting time for the role of artificial intelligence to benefit scientific discovery and humanity. The compounds come with a wealth of clinical and biological data that enables BenevolentAI to have further insights into the biology of diseases. Securing these novel clinical drug candidates perfectly aligns with our strategy of developing first-in-class and best-in-class stratified medicines to help patients with high unmet needs."


'/>"/>
SOURCE BenevolentAI
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. BioElectronics Invited to Present Chronic Pain Patient Observation Study at the British Pain Society Congress
2. Monopar Therapeutics Announces Founder And CEO Chandler Robinson Awarded The British Councils Education U.K. Alumni Award
3. Cannabis Science, Inc. (CBIS) In Final Negotiations To Acquire British Columbia Company That Has Submitted Marihuana For Medical Purposes License Application To Health Canada
4. Smithsonians "Bionic Man" Documentary Featuring the SynCardia Total Artificial Heart Earns British Film Award
5. News Update: After 555 Days On The SynCardia Artificial Heart, Stan Larkin Is Now At Home With His Donor Heart
6. TrueCare24 Unveils Artificial Intelligence-Driven Healthcare Platform
7. Eight of The Best Total Artificial Heart Centers Honored by SynCardia
8. Worlds Leading Artificial Heart Center, La Pitié Hospital, Paris, Celebrates 30 Years and 249 Implants of the SynCardia Total Artificial Heart
9. New York Times Posts Retro Report Documentary: The Total Artificial Heart - From 1st Implant to Worlds Most Used Artificial Heart
10. Global Artificial Tears Industry
11. Insulet Announces Development Partner for the OmniPod Artificial Pancreas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2018)... ... September 12, 2018 , ... Patient experience and population health ... its Population Engage patient experience suite. Express Surveys are short, streamlined patient ... organization a wealth of strategic and tactical knowledge in order to take meaningful ...
(Date:9/12/2018)... ... September 12, 2018 , ... Lifetime Wellness , a ... announces the launch of a new online store to offer exclusive aromatherapy products to ... , “We’re thrilled to open our online store to offer our custom aromatherapy to ...
(Date:9/12/2018)... ... September 13, 2018 , ... Donaldson Plastic Surgery has been included on ... Business First's Fast 50 list of central Ohio's fastest growing businesses. The plastic surgery ... of 81 percent. It is the only medical practice and plastic surgery office to ...
Breaking Medicine Technology:
(Date:9/24/2018)... ... September 24, 2018 , ... Paris-based My ... customers’ doorsteps. Its roster of talented chefs works constantly to create innovative, balanced ... In addition to its standard weekly meals, My Cuistot is happy to customize ...
(Date:9/22/2018)... ... September 21, 2018 , ... From 1991 to 2012, Works of ... Carolina’s programs and clients, all thanks to the generous artists, sponsors, and patrons who ... 1991—about HIV/AIDS, about community response to HIV/AIDS, about the Alliance of AIDS Services - ...
(Date:9/22/2018)... Calif. (PRWEB) , ... September 22, 2018 , ... The ... is the serious health risk that particularly affects older adults – the risk of ... (CDC):, Every second of the day and adult aged 65 and older falls in ...
(Date:9/15/2018)... , ... September 14, 2018 , ... ... Diseases." This campaign will showcase the innovative work being done within rare diseases ... future therapies for those living with rare diseases. , Clay ...
(Date:9/13/2018)... ... September 13, 2018 , ... Pulsara is honored to be represented ... Cycle Conference on September 19-22 in Chicago. Dr. Woodson, ER Physician and Founder/CEO ... a talk titled, “Your Clinical Communication & Collaboration (CC&C) is Not Enough: Why You ...
Breaking Medicine News(10 mins):